Anchored PDE4 regulates chloride conductance in wild-type and Δf508-CFTR human airway epithelia

FASEB Journal

Volumn 28, Issue 2, 2014, Pages 791-801

  Blanchard, Elise ^a   Zlock, Lorna ^a   Lao, Anna ^a   Mika, Delphine ^a   Namkung, Wan ^a,b,c   Xie, Moses ^a   Scheitrum, Colleen ^a   Gruenert, Dieter C ^a   Verkman, Alan S ^a,b   Finkbeiner, Walter E ^a   Conti, Marco ^a   Richter, Wito ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Yonsei University   (South Korea)

Author keywords

CAMP; Corrector; Cyclic nucleotide phosphodiesterase; Cystic fibrosis

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ISOPRENALINE; PHOSPHODIESTERASE IV; AMILORIDE; CHLORIDE; CILOSTAMIDE; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR DELTA F508; QUINOLONE DERIVATIVE; ROLIPRAM;

ARTICLE; BRONCHUS MUCOSA; CELL STIMULATION; CELLULAR DISTRIBUTION; CHANNEL GATING; CHLORIDE CONDUCTANCE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HOMOZYGOTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REGULATORY MECHANISM; RESPIRATORY EPITHELIUM; WILD TYPE; CELL CULTURE; CORRECTOR; CYSTIC FIBROSIS; DRUG EFFECT; EPITHELIUM; IMMUNOPRECIPITATION; METABOLISM; RESPIRATORY TRACT MUCOSA;

CAMP; CORRECTOR; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYSTIC FIBROSIS;

AMILORIDE; CELLS, CULTURED; CHLORIDES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIUM; HUMANS; IMMUNOPRECIPITATION; QUINOLONES; RESPIRATORY MUCOSA; ROLIPRAM;

EID: 84897073798     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.13-240861     Document Type: Article

References (65)

1. Verkman, A. S., and Galietta, L. J. (2009) Chloride channels as drug targets. Nat. Rev. Drug Discov. 8, 153-171
2. Kim Chiaw, P., Eckford, P. D., and Bear, C. E. (2011) Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy. Essays Biochem. 50, 233-248
3. Lukacs, G. L., and Verkman, A. S. (2012) CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. Trends Mol. Med. 18, 81-91
4. Kelley, T. J., Al-Nakkash, L., Cotton, C. U., and Drumm, M. L. (1996) Activation of endogenous deltaF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition. J. Clin. Invest. 98, 513-520
5. Powell, K., and Zeitlin, P. L. (2002) Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting. Adv. Drug Deliv. Rev. 54, 1395-1408
6. Schultz, B. D., Frizzell, R. A., and Bridges, R. J. (1999) Rescue of dysfunctional deltaF508-CFTR chloride channel activity by IBMX. J. Membr. Biol. 170, 51-66
7. Grubb, B., Lazarowski, E., Knowles, M., and Boucher, R. (1993) Isobutylmethylxanthine fails to stimulate chloride secretion in cystic fibrosis airway epithelia. Am. J. Respir. Cell Mol. Biol. 8, 454-460
8. Amaral, M. D. (2011) Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies. Curr. Drug Targets 12, 683-693
9. Pettit, R. S. (2012) Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Ann. Pharmacother. 46, 1065-1075
10. Rowe, S. M., Pyle, L. C., Jurkevante, A., Varga, K., Collawn, J., Sloane, P. A., Woodworth, B., Mazur, M., Fulton, J., Fan, L., Li, Y., Fortenberry, J., Sorscher, E. J., and Clancy, J. P. (2010) DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm. Pharmacol. Ther. 23, 268-278
11. Conti, M., and Beavo, J. (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76, 481-511
12. Jin, S. L., Ding, S. L., and Lin, S. C. (2012) Phosphodiesterase 4 and its inhibitors in inflammatory diseases. Chang Gung Med. J. 35, 197-210
13. Richter, W., and Conti, M. (2002) Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs). J. Biol. Chem. 277, 40212-40221
14. Richter, W., and Conti, M. (2004) The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases. J. Biol. Chem. 279, 30338-30348
15. Richter, W., Day, P., Agrawal, R., Bruss, M. D., Granier, S., Wang, Y. L., Rasmussen, S. G., Horner, K., Wang, P., Lei, T., Patterson, A. J., Kobilka, B., and Conti, M. (2008) Signaling from beta1- and beta2-adrenergic receptors is defined by differential interactions with PDE4. EMBO J. 27, 384-393
16. Richter, W., Jin, S. L., and Conti, M. (2005) Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Biochem. J. 388, 803-811
17. Zhang, L., Gallup, M., Zlock, L., Finkbeiner, W. E., and McNamara, N. A. (2013) Rac1 and Cdc42 differentially modulate cigarette smoke-induced airway cell migration through p120- catenin-dependent and -independent pathways. Am. J. Pathol. 182, 1986-1995
18. Cozens, A. L., Yezzi, M. J., Kunzelmann, K., Ohrui, T., Chin, L., Eng, K., Finkbeiner, W. E., Widdicombe, J. H., and Gruenert, D. C. (1994) CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 10, 38-47
19. Illek, B., Maurisse, R., Wahler, L., Kunzelmann, K., Fischer, H., and Gruenert, D. C. (2008) Cl transport in complemented CF bronchial epithelial cells correlates with CFTR mRNA expression levels. Cell. Physiol. Biochem. 22, 57-68
20. Xie, M., Rich, T. C., Scheitrum, C., Conti, M., and Richter, W. (2011) Inactivation of multidrug resistance proteins disrupts both cellular extrusion and intracellular degradation of cAMP. Mol. Pharmacol. 80, 281-293
21. Liu, S., Veilleux, A., Zhang, L., Young, A., Kwok, E., Laliberte, F., Chung, C., Tota, M. R., Dube, D., Friesen, R. W., and Huang, Z. (2005) Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 314, 846-854
22. Penmatsa, H., Zhang, W., Yarlagadda, S., Li, C., Conoley, V. G., Yue, J., Bahouth, S. W., Buddington, R. K., Zhang, G., Nelson, D. J., Sonecha, M. D., Manganiello, V., Wine, J. J., and Naren, A. P. (2010) Compartmentalized cyclic adenosine 3=,5=-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains. Mol. Biol. Cell 21, 1097-1110
23. Barnes, A. P., Livera, G., Huang, P., Sun, C., O'Neal, W. K., Conti, M., Stutts, M. J., and Milgram, S. L. (2005) Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J. Biol. Chem. 280, 7997-8003
24. LeSimple, P., Liao, J., Robert, R., Gruenert, D. C., and Hanrahan, J. W. (2010) Cystic fibrosis transmembrane conductance regulator trafficking modulates the barrier function of airway epithelial cell monolayers. J. Physiol. 588, 1195-1209
25. Cheng, J., Cebotaru, V., Cebotaru, L., and Guggino, W. B. (2010) Syntaxin 6 and CAL mediate the degradation of the cystic fibrosis transmembrane conductance regulator. Mol. Biol. Cell 21, 1178-1187
26. Van Goor, F., Straley, K. S., Cao, D., Gonzalez, J., Hadida, S., Hazlewood, A., Joubran, J., Knapp, T., Makings, L. R., Miller, M., Neuberger, T., Olson, E., Panchenko, V., Rader, J., Singh, A., Stack, J. H., Tung, R., Grootenhuis, P. D., and Negulescu, P. (2006) Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am. J. Physiol. Lung Cell. Mol. Physiol. 290, L1117-L1130
27. Loo, T. W., Bartlett, M. C., Wang, Y., and Clarke, D. M. (2006) The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants. Biochem. J. 395, 537-542
28. Van Goor, F., Hadida, S., Grootenhuis, P. D., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., Wine, J. J., Frizzell, R. A., Ashlock, M., and Negulescu, P. A. (2011) Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. U. S. A. 108, 18843-18848
29. Amaral, M. D. (2005) Processing of CFTR: traversing the cellular maze-how much CFTR needs to go through to avoid cystic fibrosis? Pediatr. Pulmonol. 39, 479-491
30. Ramalho, A. S., Beck, S., Meyer, M., Penque, D., Cutting, G. R., and Amaral, M. D. (2002) Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 27, 619-627
31. Monterisi, S., Favia, M., Guerra, L., Cardone, R. A., Marzulli, D., Reshkin, S. J., Casavola, V., and Zaccolo, M. (2012) CFTR regulation in human airway epithelial cells requires integrity of the actin cytoskeleton and compartmentalized cAMP and PKA activity. J. Cell Sci. 125, 1106-1117
32. Watson, M. J., Worthington, E. N., Clunes, L. A., Rasmussen, J. E., Jones, L., and Tarran, R. (2011) Defective adenosinestimulated cAMP production in cystic fibrosis airway epithelia: a novel role for CFTR in cell signaling. FASEB J. 25, 2996-3003
33. Li, C., and Naren, A. P. (2005) Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners. Pharmacol. Ther. 108, 208-223
34. Lee, J. H., Richter, W., Namkung, W., Kim, K. H., Kim, E., Conti, M., and Lee, M. G. (2007) Dynamic regulation of cystic fibrosis transmembrane conductance regulator by competitive interactions of molecular adaptors. J. Biol. Chem. 282, 10414-10422
35. Richter, W., Mika, D., Blanchard, E., Day, P., and Conti, M. (2013) beta1-adrenergic receptor antagonists signal via PDE4 translocation. EMBO Rep. 14, 276-283
36. Farinha, C. M., King-Underwood, J., Sousa, M., Correia, A. R., Henriques, B. J., Roxo-Rosa, M., Da Paula, A. C., Williams, J., Hirst, S., Gomes, C. M., and Amaral, M. D. (2013) Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR Rescue by VX-809 and suggest multiple agents for full correction. Chem. Biol. 20, 943-955
37. Okiyoneda, T., Veit, G., Dekkers, J. F., Bagdany, M., Soya, N., Xu, H., Roldan, A., Verkman, A. S., Kurth, M., Simon, A., Hegedus, T., Beekman, J. M., and Lukacs, G. L. (2013) Mechanism- based corrector combination restores DeltaF508-CFTR folding and function. Nat. Chem. Biol. 9, 444-454
38. Van Goor, F., Hadida, S., Grootenhuis, P. D., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., Zhou, J., McCartney, J., Arumugam, V., Decker, C., Yang, J., Young, C., Olson, E. R., Wine, J. J., Frizzell, R. A., Ashlock, M., and Negulescu, P. (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. U. S. A. 106, 18825-18830
39. McPhail, G. L., and Clancy, J. P. (2013) Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. Drugs Today 49, 253-260
40. Stoltz, D. A., Rokhlina, T., Ernst, S. E., Pezzulo, A. A., Ostedgaard, L. S., Karp, P. H., Samuel, M. S., Reznikov, L. R., Rector, M. V., Gansemer, N. D., Bouzek, D. C., Alaiwa, M. H., Hoegger, M. J., Ludwig, P. S., Taft, P. J., Wallen, T. J., Wohlford- Lenane, C., McMenimen, J. D., Chen, J. H., Bogan, K. L., Adam, R. J., Hornick, E. E., Nelson, G. A. t., Hoffman, E. A., Chang, E. H., Zabner, J., McCray, P. B., Jr., Prather, R. S., Meyerholz, D. K., and Welsh, M. J. (2013) Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs. J. Clin. Invest. 123, 2685-2693
41. Calverley, P. M., Rabe, K. F., Goehring, U. M., Kristiansen, S., Fabbri, L. M., and Martinez, F. J. (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374, 685-694
42. Fabbri, L. M., Calverley, P. M., Izquierdo-Alonso, J. L., Bundschuh, D. S., Brose, M., Martinez, F. J., and Rabe, K. F. (2009) Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 374, 695-703
43. Kelley, T. J., al-Nakkash, L., and Drumm, M. L. (1995) CFTRmediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 13, 657-664
44. Shakur, Y., Fong, M., Hensley, J., Cone, J., Movsesian, M. A., Kambayashi, J., Yoshitake, M., and Liu, Y. (2002) Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc. Drugs Ther. 16, 417-427
45. Guggino, W. B., and Stanton, B. A. (2006) New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat. Rev. Mol. Cell Biol. 7, 426-436
46. Huang, P., Trotter, K., Boucher, R. C., Milgram, S. L., and Stutts, M. J. (2000) PKA holoenzyme is functionally coupled to CFTR by AKAPs. Am. J. Physiol. Cell Physiol. 278, C417-422
47. Thelin, W. R., Kesimer, M., Tarran, R., Kreda, S. M., Grubb, B. R., Sheehan, J. K., Stutts, M. J., and Milgram, S. L. (2005) The cystic fibrosis transmembrane conductance regulator is regulated by a direct interaction with the protein phosphatase 2A. J. Biol. Chem. 280, 41512-41520
48. Conti, M., Richter, W., Mehats, C., Livera, G., Park, J. Y., and Jin, C. (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J. Biol. Chem. 278, 5493-5496
49. Bolger, G. B., Baillie, G. S., Li, X., Lynch, M. J., Herzyk, P., Mohamed, A., Mitchell, L. H., McCahill, A., Hundsrucker, C., Klussmann, E., Adams, D. R., and Houslay, M. D. (2006) Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5. Biochem. J. 398, 23-36
50. Page, C. P., and Spina, D. (2011) Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handbook Exp. Pharmacol. 204, 391-414
51. Richter, W., Menniti, F. S., Zhang, H. T., and Conti, M. (2013) PDE4 as a target for cognition enhancement. Expert Opin. Ther. Targets, 17 1011-1027
52. Cantin, A. M., Hanrahan, J. W., Bilodeau, G., Ellis, L., Dupuis, A., Liao, J., Zielenski, J., and Durie, P. (2006) Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am. J. Respir. Crit. Care. Med. 173, 1139-1144
53. Clunes, L. A., Davies, C. M., Coakley, R. D., Aleksandrov, A. A., Henderson, A. G., Zeman, K. L., Worthington, E. N., Gentzsch, M., Kreda, S. M., Cholon, D., Bennett, W. D., Riordan, J. R., Boucher, R. C., and Tarran, R. (2012) Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J. 26, 533-545
54. Sloane, P. A., Shastry, S., Wilhelm, A., Courville, C., Tang, L. P., Backer, K., Levin, E., Raju, S. V., Li, Y., Mazur, M., Byan-Parker, S., Grizzle, W., Sorscher, E. J., Dransfield, M. T., and Rowe, S. M. (2012) A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS One 7, e39809
55. Dransfield, M. T., Wilhelm, A. M., Flanagan, B., Courville, C., Tidwell, S. L., Raju, S. V., Gaggar, A., Steele, C., Tang, L. P., Liu, B., and Rowe, S. M. (2013) Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. Chest 144, 498-506
56. Elizur, A., Cannon, C. L., and Ferkol, T. W. (2008) Airway inflammation in cystic fibrosis. Chest 133, 489-495
57. Nichols, D., Chmiel, J., and Berger, M. (2008) Chronic inflammation in the cystic fibrosis lung: alterations in interand intracellular signaling. Clin. Rev. Allergy Immunol. 34, 146-162
58. Nichols, D. P., Konstan, M. W., and Chmiel, J. F. (2008) Anti-inflammatory therapies for cystic fibrosis-related lung disease. Clin. Rev. Allergy Immunol. 35, 135-153
59. Francis, S. H., Houslay, M. D., and Conti, M. (2011) Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action. Handbook Exp. Pharmacol. 204, 47-84
60. Houslay, M. D., Schafer, P., and Zhang, K. Y. (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov. Today 10, 1503-1519
61. Zhang, K. Y., Ibrahim, P. N., Gillette, S., and Bollag, G. (2005) Phosphodiesterase-4 as a potential drug target. Expert Opin. Ther. Targets 9, 1283-1305
62. Giembycz, M. A., and Field, S. K. (2010) Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des. Devel. Ther. 4, 147-158
63. Hatzelmann, A., Morcillo, E. J., Lungarella, G., Adnot, S., Sanjar, S., Beume, R., Schudt, C., and Tenor, H. (2010) The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 23, 235-256
64. Giembycz, M. A. (2008) Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br. J. Pharmacol. 155, 288-290
65. Srivani, P., Usharani, D., Jemmis, E. D., and Sastry, G. N. (2008) Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design. Curr. Pharm. Des. 14, 3854-3872